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Abstract 
Hepatitis C virus (HCV) is a single strained RNA virus formally identified as the main cause of non-A non-B 
chronic hepatitis in April 1989. There are no accurate evidence about the actual prevalence of HCV chronic 
infection, however recent meta-analyses estimate that currently about 130-150 million people lives with chronic 
hepatitis C and that HCV causes about 500,000 deaths each year. The prevalence of infection is the highest in 
lower and middle income countries where incidence of new case of infection are mainly associated to iatrogenic 
transmission. In developed countries the infection is mainly due to at risk exposures and prevalence is still high 
among special groups  such as person who injects drugs and jailed people. There is no vaccine against HCV, 
however since recently new drugs with a direct antiviral activity (DAA) has made chronic hepatitis C a curable 
condition. These drugs assure all oral therapy with efficacy approaching 100%, optimal tolerability and no absolute 
contraindications. The extraordinary clinical performance of DAA has renew the hope for developing public health 
interventions to reduce the burden of diseases and cut down new HCV infections at global level. We review the 
global epidemiology of HCV and intervention strategies for achieving global control of HCV infection. We also 
summarize the key elements of the World Health Organization’s first-ever global health sector strategy for 
addressing the viral hepatitis pandemic, 2016-2021. 
Introduction 
Hepatitis C virus (HCV) is a single strained RNA virus formally identified as the main cause of non-A non-B 
hepatitis in April 1989.[1] It is a leading cause of liver related mortality worldwide and was estimated to have 
caused 333 000 deaths in 1990, 499 000 in 2010 and 704 000 in 2013.[2-4] Humans are the only natural host of 
HCV. Symptoms of acute infection are generally mild and the majority of cases of acute infection are 
asymptomatic and remain undiagnosed. Spontaneous clearance of acute HCV infection occurs within six months 
of infection in 15–45% of infected individuals in the absence of treatment.[5] 
Infection with HCV does not result in long term immunity and re-infection after recovery has been largely 
reported.[6] Furthermore, in settings with high HCV prevalence, mixed HCV genotype infections, a consequence 
of multiple exposures, are also frequent.[7] The inability to mount an effective protective immune response and 
the high variability of HCV genotypes (7 genotypes and 67 confirmed subtypes)[8] has hindered progress in 
vaccine development. However, new oral direct-acting antivirals (DAA) treatments have transformed the 
treatment of HCV, with cure rates higher than 90%, using short duration oral regimens and providing pan-
genotypic efficacy.[9]-[10]-[11] The extraordinary clinical efficacy of DAA is now being advanced as a public 
health intervention to control the HCV infection at global level. [11-12] 
We review the global epidemiology of HCV and intervention strategies for achieving global control of HCV 
infection. We also summarize the key elements of the World Health Organization (WHO) first-ever global health 
sector strategy for addressing the viral hepatitis pandemic, 2016-2021. 
  
Methodological notes 
This narrative review represents experts’ personal interpretation of the different perspectives about the public 
health strategies to scale-up the control of HCV epidemic at global level after the introduction of DAA. 
Information used to write the manuscript was collected from: PubMed search, Scopus, Web of Science, WHO 
website, google scholar, hand searches of the references of retrieved literature and personal experience of 
participating experts. 
Global epidemiology of HCV infection 
Global estimates of HCV prevalence and burden 
Hanafiah and colleagues[13] estimated that in 2005 there was an overall global prevalence of 2.8% (95% CI 2.6%-
3.1%) and in excess of 185 million persons who were HCV antibody positive (95% CI 169 to 201 million) based 
on a systematic review of 232 studies.2 A key limitation of this review was that since the focus was on regional 
picture of prevalence, the results do not capture the potential heterogeneity that exists between sub-populations 
within countries. A more recent systematic review by Gower and colleagues[14] was based on 4901 studies from 
87 countries that included unpublished reports, and that also excluded older studies. This has generated 
substantially lower estimates of global HCV antibody prevalence at 115 million cases (95% CI 92 to 149 million) 
and an HCV viraemic population of 80 million people (95% CI 64 to 103 million). 
In high income countries (HIC), the prevalence of chronic hepatitis C is generally below 2%.[13-14] However, 
there is variability and differences within countries with similar socio-economic conditions due to both differences 
a) the size and prevalence of infection in key higher risk populations, such as PWID (people who injects drugs); 
and b) access to prevention, diagnosis and treatment.[15] Even in a relatively homogenous settings such as Western 
Europe, prevalence of viraemic HCV infection may range between 0.4% (Austria, Cyprus, Germany, Denmark, 
France, United Kingdom) to 1.5% (Israel, Italy).13 
Available data indicate that countries with the highest HCV prevalence (≥5%) are mainly low-middle income 
countries (LMIC), including: Egypt 9.8%-15.0%,[16]-[17] Gabon 4.9%-11.2%;[18] Uzbekistan 11.3%, Cameron 
4.9%-13.8%,[19] Mongolia 9.6%-10.8%,[20-21] Pakistan 6.8%,[22] Nigeria 8.4%, Georgia 6.7%.[23] 
Health-care associated transmission 
In LMIC poor standards of infection control and injection safety are responsible for a significant proportion of 
new HCV infections. A nationwide systematic review and meta-analysis indicates that exposures to medical 
procedures was a major driver of HCV infection in Egypt between 1989 and 2013[24] This is confirmed by studies 
from India[25], Nigeria[26] and Gabon.[27] Several studies from LMIC report that HCV seroprevalence approaches 10–
20% among children who have been treated in hospital for malignancy, those who received haemodialysis and those who 
have undergone surgical procedures.11 It is also estimated that there are around 16 billion injections administered 
yearly around the world and 40% of these are considered to be unsafe and/or unnecessary (mainly in LMIC).[28] 
Between 2000 and 2010, there was a reduction of 83% in infections of hepatitis C virus due to unsafe injections. 
However, medical injections still account for an estimated 157,000-315,000 HCV infections annually.[29] The 
WHO global database on blood safety indicated that in 2011 39 countries did not routinely screened blood 
transfusions for blood-borne viruses.[30] 
Although, HCV outbreaks due to transmission in health care settings are uncommon in HIC, between 2008 and 
2014, the US Centers for Disease Control and Prevention reported a total of 22 HCV outbreaks associated with 
239 new cases of infection and more than 90,400 at-risk persons notified for screening.[31] HCV outbreaks within 
healthcare settings have been reported in Europe too.[32-34] A study carried out in 18 Spanish hospitals indicated 
that a medical procedure was the only exposure for 67% of new sporadic HCV infections reported between 1998 
and 2005.[35] 
HCV transmission in other groups 
PWID behaviours (sharing needles and paraphernalia) are responsible for the highest number of the infections 
among young adults at global level. A longitudinal study from UK identified a high HCV incidence (42/100 
person-years) among PWID aged less than 30 years.[36-37] Furthermore, the risk of HCV re-infection after virus 
clearance among PWID is estimated to occur at a rate between 1.8 and 46.7 cases per 100 person-years.6 HCV 
transmission and acquisition in PWID is also strongly associated with incarceration.[38] A cross sectional study 
in Ireland indicate that about 20% of PWID who had been imprisoned had their first use of drug by injection in 
prison, of them and 71% reported sharing needles while in prison.[39] 
Heterosexual transmission is unlikely to play a significant role in the HCV epidemic, nationally or regionally. A 
large prospective study carried out on 500 monogamous heterosexual couples in USA indicated that the probability 
of being infected by heterosexual contacts is about 1 in 190,000.[40] Nonetheless, HCV transmission has recently 
contributed to multiple outbreaks among HIV-positive men who have sex with men (MSM). [11,41-42] A case 
control study indicated that among HIV-positive MSM, factors independently associated with HCV infection are: 
low CD4 cell count, injecting drug use, unprotected receptive anal intercourse, sharing sex toys, fisting, sharing 
straws for snorting drugs and recent diagnosis of a sexually transmitted infection.[43] There is more limited 
evidence about the risk of HCV infectionamong HIV-negative MSM.[44] 
Mother-to-infant vertical transmission of HCV is the most common HCV transmission route in children [45] with 
a risk of about 4%-8% and 11-25% in new-borns from HCV mono-infected or HIV/HCV co-infected mothers, 
respectively.[11] Several factors have been reported to influence the transmission rate including maternal HCV 
viral load, labour duration, use of amniocentesis or foetal scalp monitoring and prolonged rupture of membranes. 
However, a systematic review of 18 observational studies comprising [32,64] participants showed that no primary 
prevention measure can significantly reduce the risk of mother-to-infant HCV transmission. [46-49] Therefore, 
pre-emptive treatment of women before pregnancy represents the best strategy to prevent peri-natal infection with 
HCV.[11] 
There is growing evidence that cosmetic practices such as tattooing or scarification may have a prominent role of 
HCV transmission. In particular, in Western Africa several studies have shown a high risk of HCV among those 
who underwent tribal scarification and traditional circumcision.[7,50] 
Opportunities for intervention and action 
Implementing evidence-based prevention interventions 
HCV transmission can be dramatically reduced through effective primary prevention interventions, including 
ensuring blood safety, enhancing infection control and provision of adequate harm reduction services. 
Firstly, although entirely preventable, transmission of HCV through the transfusions still occurs because of poor 
or absent screening.[30] Therefore, ensuring the availability of safe blood and blood products is a vital public 
health measure for every national government. Secondly, consistent implementation of infection control practices, 
including safe injection measures, staff training and effective sharps waste management will reduce transmission 
of HCV to both patients and healthcare workers. Reducing unnecessary injections is also a critical measure in 
many HCV high burden countries. Implementation of the WHO injection safety policy and global campaign, 
launched in 2015, will help to address this major public health risks.[51] Thirdly, a package of harm reduction 
services for PWID that includes sterile needle/injecting paraphernalia programmes and opioid substitution therapy 
can be highly effective in preventing the transmission of blood-borne infections.[52] Finally, other effective 
primary prevention interventions are the rapid identification and control of local outbreak by enhancing 
surveillance systems, improving infection control measures in healthcare settings.[53] 
New DAA therapy: a key strategy for achieving global HCV control 
Recent clinical trials have shown extraordinary efficacy and safety of the newest combination therapies of DAA. 
In particular all-oral therapy with nucleotide analogue inhibitors of NS5B in combination with NS5A inhibitor can 
lead to complete viral clearance of HCV in 85%-100% of patients regardless HCV genotype, stage of diseases, 
response to previous therapy and pre-existence of viral resistance.[9-11] 
ASTRAL 1[54] and ASTRAL 2[55] studies demonstrated that a 12 week treatment with sofosbuvir (NS5B 
inhibitor) and velpatasvir (NS5A inhibitor) had high level efficacy (97%-100% virus clearance) and tolerability 
(about 2% side effects) in patients with genotype 1, 2, 4, 5, 6. ASTRAL 355 study indicated that complete virus 
clearance can also be obtained in 95% of patients with genotype 3 infection by a 24 week course of sofosbuvir and 
velpatasvir with a similar safety profile. Beside ASTRAL [4,56] study provided evidence that the new DAAs are 
also effective and safe (>80% efficacy <20% severe side effect) in patients with decompensated liver disease. 
Similar pan-genotypic activity has been observed also for combination of sofosbuvir with other, already approved, 
NS5A inhibitors such as ledipasvir [9,57] and daclatasvir [9,58]. 
Complete HCV clearance is considered a proxy for HCV cure [9] and is associated with a reduction in the risk of 
liver cancer by 76% and of death from any cause by 50%.[7,9-10] In addition, from a societal perspective, HCV 
clearance offers a direct strategy to reduce the force of infection[59] and represents an important public health 
measure to control HCV at a regional and global level.[60] 
A major barrier to treatment scale-up are costs of diagnostics and drugs. Prioritization strategies have been 
proposed to optimize the impact of DAA on reducing the burden of disease in several settings.[9,61-62] One 
approach is to prioritise those with advanced liver disease to improve in the immediate patients life quality and 
survival .9-11,[63] A further approach is to target persons at highest risk of transmitting infection, regardless of 
the stage of disease, to reduce the infection pool and so prevent new infections (treatment as prevention).[9,11,64] 
This strategy may include prioritizing treatment for HCV infected persons who frequently undergo percutaneous 
procedures (e.g. renal replacement), healthcare workers who undertake exposure prone procedures (e.g. surgeons), 
PWID, HIV positive MSM, incarcerated population and child bearing women. A recent model estimates that 
doubling treatment rate of PWID, could reduce the overall incidence of HCV in Scotland to less than 50 cases/year 
in 10 years. However, prioritizing PWID rather than patients with moderate and advanced fibrosis would also 
reduce the immediate impact on burden of diseases (i.e. liver morbidity and mortality).[62] 
Infection control, elimination and eradication 
Though all infections can, in principle, be controlled only few can eradicated. [65]-[66]-[67] Three 
epidemiological conditions are considered essential to make eradication achievable: a) an effective intervention to 
interrupt transmission of the agent; b) an accurate diagnostic test to identify carriers; and that c) humans should be 
essential for the life-cycle of the agent. Although these criteria are largely met by the new DAA treatments, 
satisfaction of epidemiological conditions alone are insufficient for an eradication programme to be successful. 
Other requirements that must also be meet include: a) the local stakeholder must perceive the infection as a relevant 
health issue; b) the elimination/eradication programme must be economically convenient; and c) the 
elimination/eradication programme must be supported by adequate institutional commitment. 
In several countries, commitment for broad access to new DAAs, unrestricted by the stage of disease, is increasing 
with the view that HCV elimination is both technically feasible and socially sustainable.[68] For example, the 
Canadian government estimate that about 250,000 individuals are chronically infected with HCV. Over the next 
20 years, it is estimated that these people would require a 60% increase of healthcare expenditure due to HCV 
associated morbidity, with a lifetime cost per patient of about $64,694 excluding antiviral treatments.[69]-[70] 
This compares to a current cost of DAAs in Canada which is between $50,000-$120,000 and likely to continue 
declining over the next few years. In the scenario offering unrestricted access to DAA would save on expected 
increasing cost of HCV related morbidity[71] as well as spare future generation the risk of infection with an 
eventual economic gain in the medium and long term. LMICs are also exploring potential elimination strategies, 
including Egypt, Mongolia, Georgia and Rwanda. All such strategies should include a combined strategy of testing 
and treatment scale-up with key preventative interventions of injection safety and harm reduction services.11 
Model-based analysis demonstrates that prioritizing patients according to the stage of the disease may be the most 
effective strategy to maximize the impact of DAA in LMIC[72] where there are generally low rates of diagnosis 
and heterogeneous modes of transmission. 
Current challenges to control of HCV epidemic 
Although new opportunities provide hope for the elimination HCV, there remain several significant barriers that 
will need to be addressed to realize this goal: 
 Inadequate surveillance data: the true public health impact of the HCV is poorly understood in 
many countries making it difficult to plan for focused action and prioritize resources; [73] 
 Coverage of prevention programmes is limited: prevention programmes (which proved to be 
effective for other blood borne infections such as HIV) are generally of limited scope and 
coverage, for example, global coverage of harm reduction programmes for PWID, is less than 
10%;[74] 
 Few people know their hepatitis status and have access to treatment: early diagnosis and staging 
of chronic hepatitis disease is compromised by both the lack of simple and reliable diagnostics 
and effective testing services (it is estimated that even in Egypt, with a high-profile treatment 
programme, only 3.8% of persons with chronic HCV infection have access to test;[75] in HIC 
diagnosis rate is generally much higher, though infrequently exceed 50%);[76]-[77] 
 Medicines and diagnostics are unaffordable for most. although DAA have revolutionized the 
treatment of HCV, their high price remains a major barrier to access in most countries; 
 A public health approach to hepatitis is lacking: few countries have public health programmes 
that deliver comprehensive HCV services; [73] 
 Leadership and commitment is uneven: at present, few countries have national HCV strategies 
or plans, and even fewer have designated units and budgets within their health ministries to lead, 
guide and coordinate their hepatitis responses. [73] 
New WHO Global Health Sector Strategy on viral hepatitis 
In response to the 2010[78] and 2015[79] World Health Assembly resolutions and target 3.3 of the 2030 Agenda 
for Sustainable Development Goals,[80] WHO has recently developed the first-ever global health sector strategy 
on viral hepatitis to guide a coherent global public health response.[81] 
The strategy addresses all five hepatitis viruses (hepatitis A, B, C, D and E), but has a strong focus on hepatitis C. 
The strategy outlines a vision, goals, a series of ambitious impact targets (incidence and deaths) and service 
delivery coverage targets (access to testing and treatment, blood safety, safe injection practices and harm reduction 
services) for 2020 and 2030 towards elimination of viral hepatitis as a major public health concern, as well as 
priority actions to be taken by countries and WHO to achieve these targets. 
The Global health sector hepatitis strategy 2016–2021 would be expected to deliver a 70% reduction in HCV 
incidence by 2030 (50% reduction by 2020) compared with 2010, and 60% reduction in HCV-related deaths by 
2030 compared with 2010, which will require reaching ambitious service coverage milestones: in blood safety, 
safe injection practices, harm reduction services and in access to HCV diagnosis and treatment. In particular, the 
strategy calls for a major increase in diagnosis of chronic infection, and for treatment coverage ofeligible persons 
by 2030. The priority actions are summarized in five strategic directions and are summarized in figure 1. 
Conclusions 
With effective global scale-up of the new DAA treatment alongside evidence-based interventions for primary 
prevention, control of HCV is a feasible goal. [82]-[83] Complete eradication of HCV although desirable is not 
yet in reach. Key barriers to elimination especially in LMICs that will need to be addressed include current low 
implementation of primary prevention measures, poor definition of local HCV epidemiology and relatively weak 
diagnostics capability. A key challenge is how to make the treatments affordable and ensure that they are accessible 
to all who need them. The demand for affordable treatment for HCV requires comprehensive price reduction 
strategies for medicines and diagnostics, that could include fostering generic competition, including voluntary 
licences, differential pricing and direct price negotiations with manufacturers.[84]-[85] The global response in 
HCV control can also learn from successful public health programmes in other areas, including those for HIV and 
tuberculosis. Innovative HIV service delivery approaches for marginalized and vulnerable populations, for 
example, can be adapted for reaching those key populations most affected by HCV. Effective implementation of 
the global hepatitis strategy will depend on effective collaboration with partners, including multilateral and 
bilateral donor and development agencies, funds and foundations, and civil society. 
  
Figure 
Figure 1. Framework for the global health sector strategy on viral hepatitis, 2016-2021 
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